{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:45:44Z","timestamp":1777484744344,"version":"3.51.4"},"reference-count":68,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Rare epidermal growth factor receptor (EGFR) mutations other than G719X, S768I, and L861Q are infrequently represented in clinical trials. The efficacy of tyrosine kinase inhibitors (TKIs) against these uncommon variants, either alone or in combination with common mutations, remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients with advanced-stage non-small cell lung cancer (NSCLC) harboring non-major uncommon EGFR mutations who received first-line afatinib between January 2018 and October 2024. Patients with only TKI-sensitive mutations (Del19, L858\u00a0R, G719X, S768I, and L861Q) and without additional rare variants were excluded. The primary endpoints were the objective response rate (ORR) and progression-free survival (PFS). The secondary endpoint was the duration of response (DOR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 44 patients, 36.4% had solitary non-major uncommon mutations. The overall ORR and the disease control rates were 65.9% and 86.4%, respectively. The ORR by subgroup was 75.0% for patients with non-major uncommon mutations plus EGFR-TKI-sensitive mutations, and 55.0% for patients with dual or solitary uncommon mutations. At a median follow-up time of 21.9\u00a0months, the median PFS was 11.5\u00a0months (95% CI: 7.5-22.6). Patients with non-major uncommon mutations co-occurring with TKI-sensitive mutations had a longer median PFS (17.7\u00a0months; 95% CI: 13.6\u2013NR) than those harboring non-major mutations alone (either single or dual) (9.1\u00a0months; 95% CI: 4.6\u2013NR),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04. The median duration of response was 16.1\u00a0months (95% CI: 10.3\u2013NR) with a median follow-up time of 16.8\u00a0months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Afatinib demonstrated encouraging efficacy in NSCLC patients with nonmajor uncommon EGFR mutations other than G719X, S768I, and L861Q, regardless of whether the mutations were solitary or compound. Comprehensive EGFR mutation profiling is crucial for identifying uncommon EGFR mutation patients likely to benefit significantly from afatinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748251386133","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:05:16Z","timestamp":1761109516000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evidence for First-Line afatinib in Advanced Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations Other than G719X\/L861Q\/S768I"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3585-8460","authenticated-orcid":false,"given":"Thanh Ha","family":"Vu","sequence":"first","affiliation":[{"name":"Hanoi Medical University"},{"name":"Vietnam National Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoa Thai","family":"Thi Nguyen","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"To Van","family":"Ta","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hanoi Medical University, Hanoi, Viet Nam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3953-6729","authenticated-orcid":false,"given":"Minh Cong","family":"Truong","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thang Bui","family":"Xuan","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anh Tuan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Hanoi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cao Van","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang Thuy","family":"Thi Nguyen","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuyet Thi","family":"Doan","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh Thi","family":"Vu","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dung Khac","family":"Dinh","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giang Vinh","family":"Le","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital"},{"name":"Department of Epidemiology, Hanoi Medical University, Hanoi, Viet Nam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung Huy","family":"Hoang","sequence":"additional","affiliation":[{"name":"Hanoi Medical University"},{"name":"Vietnam National Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Khanh","family":"Duong","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linh Khanh","family":"Dao","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.079"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-235"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.834704"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","unstructured":"LUX-Lung 3. A randomized open-label phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol. doi:10.1200\/jco.2012.30.18_suppl.lba7500. Accessed 10 July 2024.","DOI":"10.1200\/jco.2012.30.18_suppl.lba7500"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.8016"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3779\/10.3779\/j.issn.1009-3419.2023.102.36"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00026-1"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2021.602726"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(21)01987-0"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3408"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03898-1"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.12.017"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt418"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5013"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29010024"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104407"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.09.015"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30060405"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13787"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101994"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00114-8"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1145"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2017.06.09"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.13868"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01372"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00009313"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.954026"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.1170"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.912426"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00426"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.5b00444"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e21001"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.05.036"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182781e35"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1046"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S118071"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4902-24"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.1265"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","unstructured":"(PDF) Efficacy of EGFR-TKI sequential therapy in patients with EGFR exon 19 insertion-positive non-small-cell lung cancer: a case report. ResearchGate. Published online October 22 2024. doi:10.12998\/wjcc.v10.i6.1883","DOI":"10.12998\/wjcc.v10.i6.1883"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-6593-1"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0780"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.1094"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2506"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1129629"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S328839"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.425"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.11.018"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182779d18"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0226"},{"key":"e_1_3_4_52_2","unstructured":"RYBREVANT\u00ae (amivantamab-vmjw) HCP. Accessed March 1 2025.https:\/\/www.rybrevanthcp.com\/clinical-data\/papillon\/"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007205"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.593852"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S268694"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan6566"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01108-3"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-023-01401-3"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e12080"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001523"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.01.010"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1159308"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.511"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1570"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1757"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S341001"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.2174\/0113892029308327240612110334"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpan.2024.12.001"},{"key":"e_1_3_4_69_2","doi-asserted-by":"crossref","unstructured":"Fang Y Kong Y Rong G Luo Q Liao W Zeng D. Systematic investigation of tumor microenvironment and antitumor immunity with IOBR. Med Research. 2025 Jun;1(1):136-40.","DOI":"10.1002\/mdr2.70001"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748251386133","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748251386133","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748251386133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:24:07Z","timestamp":1777386247000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748251386133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":68,"alternative-id":["10.1177\/10732748251386133"],"URL":"https:\/\/doi.org\/10.1177\/10732748251386133","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/10732748251386133\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251386133\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251386133\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251386133\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251386133\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251386133\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251386133\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748251386133\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"10732748251386133"}}